Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Limited reported FY26 revenue of INR 92,035 Mn, up 16.6% YoY, with international revenue growing 22.2% to INR 51,766 Mn. Domestic revenue rose 10.0% to INR 40,270 Mn, driven by chronic therapy leadership and strong brand positions in gynaecology, cardiology, and anti-diabetics. The company achieved 33.1% PAT growth, with a 120 bps increase in PAT margin to 10.2%. International operations, including Europe (+25.5%), Canada (+18.7%), and RoW (+21.8%), benefited from complex injectables, biosimilars, and strategic partnerships. R&D investments focus on chiral molecules, biologics, and novel delivery systems, with 548 qualified scientists and 220 patents. Manufacturing capabilities support global execution, with 13 facilities compliant with global standards. Sustainability efforts include 64.7% renewable energy use and 84.3% waste recovery in FY26. The board includes experienced leaders with deep pharma and governance expertise. The presentation highlights strategic priorities: deepening domestic franchises, scaling international portfolios, and translating R&D into commercial launches. Forward-looking statements include growth targets and pipeline developments, but risks such as regulatory changes and supply chain challenges are noted.

The document emphasizes strong revenue and profit growth, strategic expansion, and robust R&D and manufacturing capabilities, reflecting a positive outlook.